| Catalog No. | HT348076 |
| Brand | abinScience |
| Tested applications | WB |
| Species reactivity | Human |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 |
| Purity | >95% purity as determined by SDS-PAGE. |
| Isotype | (VHH-VHH-hFc)-dimer |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | TRAILR2, TRAIL-R2, Death receptor 5, CD262, DR5, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9, TRAIL receptor 2, TRICK2, TNFRSF10B, KILLER, TNF-related apoptosis-inducing ligand receptor 2 |
| References | 1. Huet H, et al. TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches[J]. Cancer Research, 2012, 72(8_Supplement): 3853-3853. [HT348076] 2. Papadopoulos KP, et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemother Pharmacol. 2015;75(5):887-895. [HT348076] |
| Purification | Protein A/G purified from cell culture supernatant. |
| Biological activity | TAS266 is up to 1000-fold more potent than cross-linked DR5 antibody or TRAIL at inducing cell death in cancer cell lines via DR5 activation, with faster downstream caspase activation kinetics [1]. TAS266 potently induces death in human tumor cell lines, with potency ≥1000-fold greater than cross-linked DR5 antibody LBY135 or TRAIL [2]. TAS266 (200 mg/kg; twice weekly) shows no target organ toxicity including hepatotoxicity in cynomolgus monkeys after administration, with its biological activity remaining intact [2]. TAS266 (single dose; weekly) induces tumor regression in a variety of tumor xenograft models, and its antitumor activity with weekly administration is superior to that of DR5 agonist antibodies in pancreatic cancer and colon cancer xenograft models [2]. . Maintained bioactivity despite presence of preexisting or treatment-emergent TAS266-binding IgG antibodies in some animals. . Exhibited superior anti-tumor activity compared with a DR5 agonist antibody in patient-derived pancreatic and colon xenograft models. |
| Endotoxin level | < 10 EU/mg |
| Expression system | Mammalian cells |
| Accession | O14763 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternative name | TAS266 |
| Clone ID | TAS266 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 (LALAPG) Recombinant Isotype Control Antibody (HyHEL-10) (HP688307) Human IgG1 (LALA) Recombinant Isotype Control Antibody (HyHEL-10) (HP688107) |
Anti-Human TRAIL R2/TNFRSF10B Reference Antibody (TAS266, RUO)
Overview
Images
 Bioactivity |
Detects Human CD262/TNFRSF10B/TRAIL-R2/DR5 in indirect ELISAs. |
 SDS-PAGE |
SDS-PAGE for Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (TAS266) |
 Western blot |
Western blot analysis was performed using anti-CD262/TNFRSF10B/DR5 monoclonal antibody at 1μg/ml on various samples. Lane 1: recombinant human CD262/TNFRSF10B/DR5 (Catalog No: HT348021), 50ng Lane 2: recombinant human CD262/TNFRSF10B/DR5 (Catalog No: HT348021), 30ng |